TICKERNERD
Menu
IRDIRDHealthcare · Biotechnology

IRD Stock Forecast: Opus Genetics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$6.04
−0.49% on the day

The 18 Wall Street analysts covering Opus Genetics, Inc. hold a median 12-month price target of $12 — +98.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$502.5M
Ticker Nerd rank
58 / 100
Median analyst target
$12
Analysts covering
18
Revenue$755K−73.8% y/y
Operating income−$16.5M
Net income−$8.1M
Free cash flow−$11.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+31.3%
1M
+55.7%
YTD
+200.5%
1Y
+328.4%
From 52W high
−0.5%
From 52W low
+340.9%
$1.37
$6.07
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IRD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Opus Genetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
58 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Volatility
76
Growth
67
Accruals
66
Value
62
Revisions
56
Size
53
Quality
19
Issuance
5

Momentum (99): The shares have been drifting up relative to others.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IRD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IRD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26IRDHigh $20Median $12Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
18 Buy0 Hold0 Sell
Low $8Median $12High $20

The green dot is the last close — the median target sits +98.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
10 Sept 2026WedbushMaintainsOutperform$10 → $13
9 Sept 2026BTIGReiteratesBuy$12
9 Sept 2026Chardan CapitalMaintainsBuy$13 → $16
9 Sept 2026HC Wainwright & Co.ReiteratesBuy$8.00
9 Sept 2026OppenheimerMaintainsOutperform$10 → $20
7 Aug 2026RBC CapitalMaintainsOutperform$10 → $9.00
7 Aug 2026RBC CapitalMaintainsOutperform—
29 July 2026TD CowenInitiatesBuy—
29 July 2026TD CowenInitiatesBuy—
6 July 2026BTIGReiteratesBuy$12
6 July 2026BTIGReiteratesBuy—
6 July 2026Chardan CapitalMaintainsBuy—
6 July 2026Chardan CapitalMaintainsBuy$13
18 June 2026Chardan CapitalMaintainsBuy—
17 June 2026HC Wainwright & Co.ReiteratesBuy—
16 June 2026BTIGReiteratesBuy—
15 June 2026CitizensReiteratesMarket Outperform—
4 June 2026GuggenheimInitiatesBuy—
21 May 2026Leerink PartnersInitiatesOutperform—
13 May 2026CitizensMaintainsMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IRD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IRD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Opus Genetics, Inc. returned +328.4% against +17.5% for the S&P 500, dividends included.

IRD vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Oct 25Jan 26Apr 26Jul 26IRDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IRD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
7
Analysts cutting
2
Fundamentals

Opus Genetics, Inc. (IRD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.6×

Cheaper than 92% of US stocks

Price / sales
51.0×

Cheaper than 5% of US stocks

Price / book
−44.6×

Cheaper than 99% of US stocks

EV / EBITDA
−8.9×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
−73.8%

Higher than 3% of US stocks

Earnings growth (YoY)
−73.8%

Higher than 6% of US stocks

Gross margin
—
Operating margin
−2182.8%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−4796.5%

Higher than 1% of US stocks

Return on assets
−48.1%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Opus Genetics, Inc. (IRD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Opus Genetics, Inc. has a market value of $502.5M and an enterprise value of $449.9M.

  • Revenue in the twelve months to 30 June 2026: $9.9M. The latest quarter shrank 73.8% year on year.

  • Net income over the same four quarters: −$107.6M, a −1091.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$40.7M.

  • Opus Genetics, Inc. spent $149K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 82.6M.

  • Trailing P/E: −7.6×; forward P/E: −8.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Opus Genetics, Inc. employs 27 people — $365K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

IRD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IRDOpus Genetics, Inc.$502.5M
58
ENTXEntera Bio Ltd.$491.7M
49
ZURAZura Bio Ltd.$494.3M
32
ARTVArtiva Biotherapeutics, Inc.$496.6M
38
VOGXVogenx, Inc.$485.9M
1
EIKNEikon Therapeutics, Inc.$483.7M
1
OVIDOvid Therapeutics, Inc.$502.1M
67

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Opus Genetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IRD news & analysis

Opus Genetics: A Resounding Study Success Merits A Higher Valuation

Seeking Alpha · 10 Sept 2026positive

Opus Genetics received a Buy rating from a Seeking Alpha analyst following a stock surge driven by positive Phase 1/2 data for OPGx-BEST1 in BEST1-related retinal diseases, which showed clinically meaningful visual improvements and strong safety in all Cohort 1 patients. The company's cash runway extends into 2029, supporting ongoing pivotal studies.

Why it matters — Positive early-stage efficacy and safety data for OPGx-BEST1, combined with a cash runway into 2029, support continued progress toward pivotal studies in retinal disease areas that currently have no approved therapies.

Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript

Seeking Alpha · 10 Sept 2026neutral

Opus Genetics, Inc. (IRD) discussed topline results from Cohort 1 of its BEST1 Phase I/II gene therapy trial, as detailed in a Seeking Alpha transcript of the discussion.

Why it matters — The topline results from the first cohort of this Phase I/II trial represent a key early data point for investors monitoring the progress of Opus Genetics' gene therapy pipeline.

Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says

Benzinga · 9 Sept 2026positive

Opus Genetics reported positive three- and six-month results from the low-dose first cohort of its Phase 1/2 BIRD-1 trial of OPGx-BEST1, showing vision improvements in patients. The company's stock rose following the announcement.

Why it matters — These early clinical results for OPGx-BEST1 suggest the gene therapy may provide vision benefits at a lower dose, which is a key milestone for IRD treatment development.

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

GlobeNewsWire · 9 Sept 2026positive

Opus Genetics announced positive low-dose Cohort 1 data from its Phase 1/2 trial of OPGx-BEST1, showing a favorable safety and tolerability profile with no serious adverse events and clinically meaningful improvements in visual function for all five participants. The company also completed a successful FDA Type C meeting aligning on a potential pivotal endpoint, with potential Phase 3 dosing in 2027 and cash runway into 2029.

Why it matters — The encouraging early safety and efficacy data, plus FDA alignment on a pivotal endpoint, could advance this gene therapy candidate toward later-stage trials for BEST1-related inherited retinal disease.

Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

GlobeNewsWire · 2 Sept 2026positive

Opus Genetics will present topline data from Phase 1/2 Cohort 1 of its OPGx-BEST1 gene therapy program during an investor webcast on September 9 at 8:00 a.m. ET. The full clinical dataset and additional analyses of visual function measures will also be presented at upcoming ophthalmology conferences.

Why it matters — This represents the first disclosure of clinical data for OPGx-BEST1, a gene therapy targeting BEST1-related inherited retinal disease, which IRD watchers closely follow for potential therapeutic progress.

FAQ

Frequently asked questions about IRD stock

What is the IRD stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Opus Genetics, Inc. have a median 12-month price target of $12, with estimates ranging from $8 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IRD stock a buy right now?

Of the 18 analysts covering Opus Genetics, Inc., 18 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Opus Genetics, Inc. 58 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IRD?

As at 12 Sept 2026, Opus Genetics, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will IRD stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +98.7% from the last close, and Ticker Nerd's factor model ranks Opus Genetics, Inc. 58 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IRD stock forecast for 2030?

No analyst covering Opus Genetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $20 over the next 12 months.

How has IRD stock performed over the past year?

Opus Genetics, Inc. returned +328.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Opus Genetics, Inc. do?

Opus Genetics, Inc. Common Stock represents an equity interest in Opus Genetics, a clinical-stage biopharmaceutical company focused on ophthalmic therapies.

What is the latest news on IRD?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "Opus Genetics: A Resounding Study Success Merits A Higher Valuation". Opus Genetics received a Buy rating from a Seeking Alpha analyst following a stock surge driven by positive Phase 1/2 data for OPGx-BEST1 in BEST1-related retinal diseases, which showed clinically meaningful visual improvements and strong safety in all Cohort 1 patients. The company's cash runway extends into 2029, supporting ongoing pivotal studies.

Company

About Opus Genetics, Inc.

Opus Genetics, Inc. Common Stock represents an equity interest in Opus Genetics, a clinical-stage biopharmaceutical company focused on ophthalmic therapies. The company develops gene therapies for inherited retinal diseases and additional small-molecule treatments for other eye disorders, including programs aimed at retinal degeneration, refractive conditions, and other vision-related diseases. Its current pipeline includes investigational candidates such as OPGx-LCA5 and OPGx-BEST1, along with other ophthalmology-focused programs targeting specific genetic retinal conditions. Opus Genetics serves the broader vision-care market through research, development, and commercialization efforts centered on restoring or preserving sight in patients with unmet medical needs. The company is headquartered in Durham, North Carolina.

CEO Dr. George Magrath M.B.A., M.D., M.S. · 27 employees · United States · https://opusgtx.com